Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 500 of 5804
-
Could a daily antibiotic stop a deadly hospital infection?
Prevention Recruiting nowThe goal of this clinical trial is to determine if oral vancomycin can prevent C.diff infection in adults who are critically ill and are at high risk of C.diff infection due to their medical conditions and being in the hospital. It will also help us learn about the safety of the …
Phase: PHASE2, PHASE3 • Sponsor: Riverside University Health System Medical Center • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo aims to supercharge weight loss in obesity trial
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Head-to-Head: which drug works better for psoriatic arthritis?
Disease control CompletedThe purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could less chemo be enough? new trial tests shorter treatment for head and neck cancer
Disease control Recruiting nowThis is a phase II, prospective, non-randomized, single-arm, multicentric study to evaluate the activity and safety of treatment with 4 cycles (instead of 6) of chemotherapy (platinum (cisplatin or carboplatin) and 5-Fluorouracil) in combination with pembrolizumab for the first-l…
Phase: PHASE2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a second ADC tame breast cancer after the first fails?
Disease control Recruiting nowThis is a prospective, open-label, phase 2 platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Mpox vaccine trial expands to children: a step toward broader protection
⭐️ VACCINE ⭐️ OngoingAll participants will receive 2 vaccinations of the same dose of Modified Vaccinia Ankara Virus (MVA-BN) vaccine 4 weeks apart (standard regimen). Serum samples for assessment of immune response will be collected at baseline (visit of first vaccination) and at 2 weeks (week 6), …
Phase: PHASE2 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:59 UTC
-
Could a rheumatoid arthritis drug ease long COVID brain fog?
Disease control Recruiting nowThe overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom…
Phase: PHASE3 • Sponsor: Wes Ely • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Lung cancer vaccine trial aims to stop tumors from coming back
Disease control Recruiting nowThe goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help p…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can donor immune cells help fight pancreatic cancer after surgery?
Disease control Recruiting nowThis is a phase I/II study which intends to characterize the safety, tolerability, and preliminary efficacy of Allogeneic Magicell-NK infusion in PDA or cholangiocarcinoma patients after surgery. Subjects will receive a total of 6 intravenous (IV) infusions of the IP on the 11th …
Phase: PHASE1, PHASE2 • Sponsor: Medigen Biotechnology Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control OngoingPfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy w…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to fight bile duct cancer
Disease control OngoingThis is a phase 3 study. All subjects are patients with unresectable locally advanced or metastatic biliary tract cancer (BTC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combinati…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Gene therapy trial aims to halt Muscle-Wasting disease
Disease control OngoingThis is an interventional study to evaluate safety and efficacy of AAV-hSMN1 in spinal muscular atrophy patients.
Phase: PHASE1, PHASE2 • Sponsor: Lantu Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Robot eye doctor could save Preemies' sight
Diagnosis CompletedThe purpose of the study is to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by healthcare providers in the neonatal intensive care unit (NICU) setting to detect more than mild R…
Phase: NA • Sponsor: Siloam Vision • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Could ketamine speed up depression relief in hospitalized patients?
Symptom relief Recruiting nowUnipolar major depressive disorder is the leading cause of disability worldwide. The most commonly used treatments for major depressive episodes (MDE) are antidepressant medications. However, they have limited efficacy and their onset of action is long, ranging between 2 to 6 wee…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 26, 2026 13:18 UTC
-
Inhaled drug offers new hope for stubborn lung infection
Disease control Recruiting nowTreatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression. The outcome of these patients is poor, and treatment is very long. Indeed, this duration is base…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Could a common arthritis drug shield transplant patients from a dangerous virus?
Disease control Recruiting nowPatients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT). The purpose of this study is to evaluate whether leflunomide can prevent cytomegalovirus (CMV) reactivation in these pat…
Phase: PHASE2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for colorectal cancer: amivantamab combo tested in 1,000 patients
Disease control Recruiting nowThe purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucov…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New IV drug aims to control bleeding risk in rare blood disorder
Disease control Recruiting nowThe main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartig…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Higher aspirin dose may better protect pregnant women from dangerous hypertension
Prevention Recruiting nowThe overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated…
Phase: PHASE4 • Sponsor: Ohio State University • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Experimental drug chidamide targets Hard-to-Treat blood cancer
Disease control Recruiting nowThis is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
Phase: PHASE2 • Sponsor: Great Novel Therapeutics Biotech & Medicals Corporation • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC